Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results from the phase Ib KEYNOTE-012 expansion cohort

Chow L.Q.M.Haddad R.Gupta S.Mahipal A.Mehra R.Tahara M.Berger R.Eder J.P.Burtness B.Lee S.-H.Keam B.Kang H.Muro K.Weiss J.Geva R.CHIA-CHI LINChung H.C.Meister A.Dolled-Filhart M.Pathiraja K.Cheng J.D.Seiwert T.Y.2022-09-152022-09-1520160732-183Xhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84995489253&doi=10.1200%2fJCO.2016.68.1478&partnerID=40&md5=31ab6170cee8cf13626ef51bb5e4484dhttps://scholars.lib.ntu.edu.tw/handle/123456789/620289Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results from the phase Ib KEYNOTE-012 expansion cohortjournal article10.1200/JCO.2016.68.1478276469462-s2.0-84995489253